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Background: Preventive efforts with improved diet and more exercise have at best decelerated increasing
prevalence of overweight and obesity in Scandinavia, and the complications call for more effective
treatments. This review is an overview of dietary supplements, medical devices (for oral use), and
pharmacological treatments approved in Scandinavian countries.
Interventions: One dietary ﬁbre supplement, glucomannan, may produce a weight loss of 0.8 kg over 3
months, but a recent meta-analysis questioned efﬁcacy. Cactus ﬁg and white bean extracts, oral com-
pounds that increase satiety by a ﬁber effect in the stomach and inhibit either fat or carbohydrate ab-
sorption, result in weight losses of ~2e3% over 3e6 months, and are generally well tolerated. The
pharmaceutical compound orlistat (a lipase inhibitor) produces weight loss of 1e2% with low-dose
(over-the-counter) and 3% with high-dose (prescription), with a long-term reduction in risk of type 2
diabetes (T2D). The GLP-agonist liraglutide enhances satiety and produces weight loss of 5e7% over 6
months to 2 years, reducing comorbidities. A naltrexone/bupropion combination produces 3e5% weight
loss, and reduces risk of T2D. A class of sodium-glucose co-transporter type 2 (SGLT2) inhibitor approved
for the management of T2D also produces a weight loss (2e4% over 3e6 months) by increased excretion
of urinary glucose.
Conclusion: The available non-pharmacological agents produce clinically relevant weight loss, but
studies are small and adverse effects are not well established. Studies of pharmacological agents that use
combinations to assess additive effects on weight loss and maintenance are lacking.
© 2016 Elsevier Ltd. All rights reserved.Obesity is an increasing health challenge at the global level, and
the Scandinavian countries are no exception. About 15e25% of the
adult population can be classiﬁed as obese (BMI > 30 kg/m2), and
the majority of the population is overweight (BMI > 25 kg/m2),
which causes numerous comorbidities, disability, and reduced life
expectancy. While prevention of weight gain, overweight and
obesity is preferred, there are only early indications of a leveling off
of the increase in prevalence, and a large part of the obese popu-
lation is seeking treatment. Many obese individuals manage to lose
weight by following various diet and exercise programs, commer-
cial weight loss plans, and using meal replacements, but there is an
increasing demand for adjunct therapy that can enhance initialxercise and Sports, Faculty of
26, 1958 Frederiksberg C,weight loss efforts and improve long term weight loss mainte-
nance. Bariatric surgery is an option for morbidly obese patients,
but the majority of obese subjects do not fulﬁll the criteria for such
surgical interventions. For some patients this gap may be bridged
with dietary supplements, medical devices, and pharmacological
compounds. The purpose of this review is to provide an update on
the management options available in Scandinavia, and present a
brief assessment of efﬁcacy and safety, and clinical directions for
choices for the individual patient.
When previously approved pharmaceutical agents such as
sibutramine and rimonabant werewithdrawn from the market due
to potential serious adverse effects, only orlistat and amfepramone
were left. However, in 2015 two new compounds were approved in
the EU for weight reduction: liraglutide 3 mg (Saxenda®), and
naltrexone/bupropion (Mysimba®). We therefore present a brief
updated summary of the use of orlistat and amfepramone, and a
section on the two novel compounds. Furthermore for patients
with S, the GLP-1 analogues and SGLT2 inhibitors are available,
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ber of dietary supplements and medical devices have been
approved for weight control, and these products are also reviewed.
We have included products available in at least two Scandinavian
countries.
1. Pharmaceutical compounds
1.1. Orlistat (Xenical®, Alli®)
Orlistat has withstood the test of time, remaining the only
approved therapy in Europe since 1998 for long-term treatment of
obesity. Orlistat potently and selectively inhibits gastric and intes-
tinal lipase, reducing intestinal fat absorption. While orlistat's in-
hibition of intestinal fat absorption is minimal when dietary fat
intake is very low, the proportion of fat excretion increases in a
dose-dependent manner with increasing dietary fat, reaching a
plateau of about 30% with the usual dose of 120 mg three times
daily (Hauptman et al., 1992). In addition, orlistat may increase
glucagon-like peptide 1 secretion (Damci et al., 2004).
1.1.1. Weight loss efﬁcacy
In a meta-analysis of 16 randomized, placebo-controlled trials of
1 year orlistat reduced body weight by 2.9 kg (95% conﬁdence
interval [CI] 2.5e3.2 kg) compared with placebo (Rucker et al.,
2007). In a recent systematic review of studies with at least 50
participants per group and at least 50% retention, an intention-to-
treat analysis found that orlistat gave a 3.4 kg greater weight loss
(3.1% of initial weight) than placebo (Yanovski and Yanovski, 2014).
Two trials of orlistat 60 mg three times daily found a 2.5 kg greater
weight loss than with placebo at 12 months (Yanovski and
Yanovski, 2014). In patients with T2D, the difference between
orlistat and placebo was about 2 kg (Norris et al., 2005; Jacob et al.,
2009).
1.1.2. Weight maintenance
In a trial in 3304 participants most of the weight loss difference
at 1 year (11.4 kg for orlistat versus 7.5 kg for placebo) was pre-
served in those that completed all four years of the study (6.9 kg for
orlistat versus 4.1 kg for placebo) (Torgerson et al., 2004). Other
trials have looked speciﬁcally at orlistat as a weight maintenance
treatment following weight loss induced by orlistat, conventional
dieting or a very low energy diet (VLED). In one trial orlistat
administered for three years after VLED signiﬁcantly reduced
weight regain compared to placebo (4.6 kg versus 7.0 kg) (Richelsen
et al., 2007). A meta-analysis found that orlistat effectively main-
tained weight loss at 12 months, with a difference of 1.8 kg (95% CI
1.06 to 2.54) compared to placebo (Dombrowski et al., 2014).
1.1.3. Glycemic control in T2D
In a retrospective analysis involving 2550 overweight or obese
patients with T2D, participants treated with orlistat for 6e12
months had signiﬁcantly larger decreases in HbA1c compared to
placebo (0.74% vs. 0.31%) (Jacob et al., 2009).
1.1.4. Prevention of T2D
In a 4-year randomized, controlled trial, orlistat added to life-
style changes resulted in a 37.3% reduction in the incidence of T2D
(Torgerson et al., 2004). Pooled data from three studies has indi-
cated that orlistat prevented progression to diabetic status in sub-
jects with impaired glucose tolerance (Heymsﬁeld et al., 2000).
1.1.5. Cardiovascular risk factors
Orlistat improves most cardiovascular risk factors. Reductions in
visceral fat (Tiikkainen et al., 2004), LDL cholesterol (Muls et al.,2001) and glycemia (Jacob et al., 2009), and improved insulin
sensitivity (Kelley et al., 2004), appear in part to be independent of
weight loss. In patients with hypertension, orlistat improved sys-
tolic blood pressure by2.5mmHg (95% CI, 4.0 to0.9mmHg) and
diastolic blood pressure by 1.9 mm Hg (95% CI 3.0e0.9 mmHg)
(Siebenhofer et al., 2013). A recent meta-analysis found that orlistat
increased adiponectin and reduced leptin and C-reactive protein
(Derosa et al., 2015).
1.1.6. Safety and tolerability
Gastrointestinal effects including oily spotting, ﬂatus with
discharge, fecal urgency and steatorrhea are common, though they
tend to subside as patients learn to adjust fat intake. The risk ratio
for discontinuation of orlistat compared to placebo due to adverse
events in randomized controlled trials was 1.59 (95% CI, 1.21e2.08),
with a number need to harm of 39 (95% CI, 25e83) (Johansson et al.,
2009). Rare cases of liver injury have been reported. However, the
UK Clinical Practice Research Datalink found no evidence of an
increased risk of liver injury (Douglas et al., 2013). Orlistat in-
terferes with the absorption of several drugs and fat-soluble vita-
mins (Filippatos et al., 2008) and may cause acute kidney injury
(Kwan et al., 2013).
1.1.7. Clinical use
Orlistat is indicated for the treatment of obesity (BMI 30 kg/
m2) or overweight (BMI 27e29.9 kg/m2) with associated risk fac-
tors, in conjunction with a modestly fat-reduced diet. Attrition
rates are high, mostly due to high cost and side effects (Padwal
et al., 2007), as well as difﬁculty in complying with dietary rec-
ommendations (Svendsen et al., 2009) and the popularity of low
carbohydrate diets. A study suggested that a low-carbohydrate
ketogenic diet leads to similar weight loss as orlistat combined
with a low fat diet (Yancy et al., 2010). Beneﬁcial long-term effects
of orlistat on cardiovascular disease parameters have not been
demonstrated.
1.2. Amfepramone
Amfepramone (diethylpropion) is approved in the EU for
treatment of obesity for short durations (4e6 weeks and no longer
than 3 months) under various brand names (Anorex®, Dobesin®,
Regenon® etc.). The drug is closely related to amphetamines and
possesses some of the same CNS stimulant properties and abuse
potential, and has been associated with serious cases of primary
pulmonary hypertension. In 1999 the Committee for Proprietary
Medicinal Products (CPMP) recommended a stop to the use of
amfepramone for obesity treatment and a stop to the sale of this
drug in EU countries. In the Scandinavian countries it is available
only in Denmark, but its use cannot be recommended.
1.3. Liraglutide 3 mg (Saxenda®)
GLP-1 is an endogenous hormone released from L-cells in the
small intestine in response to the presence of food (peptides and
monoglycerates), and it acts both as an incretin that stimulates the
postprandial release of insulin, and as a satiety hormone. It is
cleared from the bloodstream within minutes, but injectable ago-
nists have been developed that can be given once daily, or even only
once weekly, and a number of such agents have been approved for
the management of T2D (e.g. exenatide, liraglutide). GLP-1 agonists
in dosages used for treatment of T2D have been found to produce a
small weight loss (Wang et al., 2014). Liraglutide is used in the
doses 1.2 and 1.8 mg daily for T2D (Victoza®), but higher dosages
are required for a clinically relevant weight loss in obese patients
(i.e. 3 mg).
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liraglutide 3 mg daily was based on a phase II program that
demonstrated that the dose of 3mgwas effective for weight control
over one year in obese patients (Astrup et al., 2009; Scheen, 2015).
Liraglutide 3 mg produced a mean weight loss of 8 kg as compared
to 2 kg in the placebo group, and 4 kg in the orlistat reference group
(Scheen, 2015) (Fig. 1). After two years follow-up the weight loss
was 5.3 kg with liraglutide and 2.3 kg with orlistat (Fig. 1) (Astrup
et al., 2012). The groupwhich received placebo for the ﬁrst year and
subsequently switched to liraglutide achieved a weight loss that
was indistinguishable from the group which had received liraglu-
tide 3 mg from the start. After two years 52% of the patients on
liraglutide 3 mg hadmaintainedmore than 5% weight loss, and 26%
more than 10%. The prevalence of prediabetes and metabolic syn-
drome was reduced, and so were blood pressure and lipids
following liraglutide as compared with placebo (Fig. 2).1.3.2. Safety and tolerability. The effects of liraglutide are well
known from the use of lower dosages for T2D. Side effects are
mainly gastrointestinal with nausea, vomiting, obstipation, and
diarrhea, which are mild and transient in nature in most cases
(Shyangdan et al., 2010). The adverse effects can be reduced by a
slow up-titration of the dosage. Independent of dosage liraglutide
increases heart rate by 2e4 bpm, but meta-analyses have found
that liraglutide is associated with reduced incidence of cardiovas-
cular events (Monami et al., 2014). A slightly increased risk of
pancreatitis has been reported with the use of liraglutide and other
GLP-1 agonists. For liraglutide 3 mg the incidence was 0.4 cases per
100 patient-years treatment as compared to ca. 0.1% with placebo
(Pi-Sunyer et al., 2015).1.3.3. Clinical use. Victoza® which is the trade name for liraglutide
in doses of 1.2 or 1.8 mg per day is indicated for the treatment of
T2D and not indicated for the treatment of overweight or obesity.
Saxenda®, on the other hand, is the trade name for liraglutide in the
dose of 3 mg per day for the treatment of obesity or overweight
(BMI 27 kg/m2) with weight-related comorbidities. The weight
loss that occurs on diet and liraglutide during the ﬁrst 3e12 weeks
is a good predictor of the individual long term outcome, and if the
patient fails to lose at least 5% of initial body weight after 3 months
the treatment should be discontinued.
The manufacturer of liraglutide recommends that Saxenda® be
used especially for subjects with BMI 35 kg/m2 and weight-
related comorbidities such as hypertension, dyslipidemia or
obstructive sleep apnea. The argument is that this group of patientsFig. 1. The average effect of treatment of obesity by lifestyle intervention alone and in com
surgery.suffers the most from their obesity and therefore these patients are
in particular need of treatment. Generally, health authorities in
many countries have acknowledged the imminent need for treat-
ment of people with 35 kg/m2, as exempliﬁed by reimbursement
of bariatric surgery for this particular group of patients. However,
reimbursement of liraglutide through public monies is not yet
available in Scandinavia.2. Pharmaceutical combinations in obesity treatment
Several reasonably effective anti-obesity drugs have been
withdrawn from the market because of unacceptable side effects.
At the same time no novel, effective anti-obesity drug can be
foreseen. It is therefore understandable that the pharmaceutical
industry has been looking for ways to recycle old and well-
established drugs, which are already approved for other clinical
indications. This saves time and toxicology work to establish safety,
and hence is cost-effective. Two such products have recently been
developed. Qsiva® is a combination of topiramate and phenter-
mine, but in considerably lower doses than when used for their
initial indications. The observation of weight loss in patients
treated with topiramate for epilepsy led to attempts to develop
topiramate into an anti-obesity drug. This was not successful at the
usual dosage levels used because of side effects (Astrup et al., 2004),
which then led to attempts to combine low dose topiramate with
another compound instead. Phentermine has been widely used for
short-term treatment of obesity for decades. In a low dose combi-
nation the compounds were found to potentiate their effects on
weight loss, and the product was eventually released as Qnexa®,
later Qsiva® in the US and some other countries (Jordan et al., 2014).
However, European regulating authorities determined that the
potential side effects were not documented well enough and the
drug has not been approved in EU. Therefore it will not be further
discussed here. However, the other drug combination, which
indeed has been approved in the EU, will be presented below.2.1. Naltrexone/bupropion (Mysimba®)
Mysimba® is a combination of two compounds (Naltrexone
7.2 mg/bupropion 78 mg), each of which has been previously
approved for clinical indications other than weight loss. Both
compounds appear as extended release forms (ER). Naltrexone is an
opioid receptor antagonist blocking all three opioid receptors. The
compound is currently used in the treatment of alcohol depen-
dence. For this indication the dosage is 50 mg daily. Bupropion is anbination with pharmaceutical compounds, and the effect of various forms of bariatric
Fig. 2. Treatment with liraglutide 3 mg for one year induces an average weight loss of 8 kg compared to 2 kg in a placebo group. Also shown are the percentage of subjects with
weight loss of 5% and 10% in liraglutide 3 mg groups vs. placebo.
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addition to the mood effect, such as smoking cessation and as an
adjunct in treatment of attention deﬁcit hyperactivity disorder.
Bupropion is an uptake inhibitor of dopamine and noradrenaline in
the central nervous system. The drug also acts as a nicotine
antagonist on the acetylcholine receptor causing nicotine depen-
dence. The dosage for these indications ranges around 150e300mg
daily.
The combination of the two compounds has a synergistic effect
in the treatment of obesity and leads to weight reduction, although
the dose of each compound is far lower than the dosages for the
initial indications. When given together their action reduces
appetite, and possibly also increases energy expenditure, leading to
a negative energy balance and ensuing weight loss (Yanovski and
Yanovski, 2015). With weight loss the anticipated effects of
improvement of obesity-associated risk factors have been
observed. In 2015 the EU approved Mysimba® for use in the entire
EU region. In summarizing the characteristics of the drug the
committee concluded that although the weight loss effects were
modest, they were still clinically signiﬁcant.2.1.1. Clinical use
Mysimba® is indicated, as an adjunct to a reduced-calorie diet
and increased physical activity, for weight loss treatment in adult
patients (18 years) with a BMI of 30 kg/m2 (obese), or  27 kg/
m2 to < 30 kg/m2 (overweight) in the presence of one or more
weight-related co-morbidities (e.g.T2D, dyslipidemia, or controlled
hypertension). Mysimba® is administered in gradually increasing
doses from one tablet daily with a meal to the maximum dose of
two tablets twice daily. Treatment with Mysimba® should be dis-
continued after 16 weeks if patients have not lost at least 5% of their
initial body weight.2.1.2. Adverse effects
Therewas a certain concern about the possible side effects of the
drug (cardio-vascular complications and a slightly increased risk of
epileptic ﬁts) but the committee concluded that these could be
managed simply by drug withdrawal. In clinical practice modest
nausea seems to be the main side effect.2.2. Sodium-glucose co-transporter type 2 (SGLT2) inhibitors
Weight loss is of prime importance for patients with T2D, of
whom the majority are either overweight or obese. The choice of
antidiabetic medication should aim at weight neutrality or reduc-
tion, such as GLP-1 receptor agonists and sodium-glucose co-
transporter type 2 inhibitors. SLGT2 inhibitors (dapagliﬂozin, can-
agliﬂozin and empagliﬂozin, currently available in Scandinavia), are
novel antidiabetic agents that induce a small weight loss. They
increase glucose excretion into the urine and reduce hyperglycemia
by inhibiting renal SGLT2 that is responsible for the reabsorption of
most of the glucose (Scheen, 2015). The currently available SGLT2-
inhibitors have similar pharmacologic characteristics.2.2.1. Clinical efﬁcacy and use
It is well documented that SGLT2-inhibitors reduce HbA1 by
~0.7e1.0% from amean of 7.5e9.0% in T2D patients treatedwith diet
and exercise, or with any glucose-lowering agents (Scheen, 2015).
Due to the increased caloric loss associated with reduced renal
reabsorption of glucose, SGLT2-inhibitors induce weight loss in
overweight and obese patients with T2D (Barnett, 2013). An early
weight loss of 1e2 kg is usually seen as a result of osmotic and
diuretic ﬂuid loss upon the initiation of therapy by any SGLT2-
inhibitor. However, reduction of body weight by weeks 24 and
thereafter, amounting to an average of about 2e4 kg, now well-
documented up to four years, has been shown to be predomi-
nantly due to loss of fat mass.2.2.2. Safety and tolerability
In studies with SLGT2-inhibitors a slight reduction of systolic
and diastolic blood pressure has been documented. The effect of
empagliﬂozin on cardiovascular morbidity and mortality has
recently been reported in a study of 7020 patients with T2D, fol-
lowed for an average of three years. As compared to placebo,
empagliﬂozin resulted in a signiﬁcantly lower risk of cardiovascular
and total death (HR 0.62, 95% CI: 0.49 to 0.77, and 0.68, 95% CI 0.57
to 0.82), as well as hospitalization for heart failure (HR 0.65, 95% CI:
0.50 to 0.85) (Zinman et al., 2015).
SLGT2-inhibitors are usually well tolerated. They slightly in-
crease the risk of urinary tract and genital infections, which how-
ever are usually mild and clinically manageable (Scheen, 2015).
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3.1. Glucomannan (Allevo®, Kilo Trim®, XLS Medical Appetite
Reducer® etc.)
Glucomannan or konjac mannan is dietary ﬁber that has been
found to enhance satiety and produce weight loss, and it is
approved by EFSA for weight loss in EU (EFSA, 2010). Glucomannan
is a soluble-type of ﬁber that forms a viscous, gel-like mass in the
stomach when hydrated, and this gel seems to delay gastric
emptying and induce satiety, leading to a decrease in subsequent
energy intake (EFSA, 2010). EFSA concluded that in order to obtain a
weight loss at least 3 g of glucomannan should be consumed daily
in three doses of at least 1 g each, together with 1e2 glasses of
water before meals, together with an energy-restricted diet (EFSA,
2010). The target population is overweight adults. The products we
assessed on the market did not declare the content ofTable 1
Approved dietary supplements, medical devices and pharmacotherapy for management
Compound Mechanism of action Effects on weight
above placebo
A
Dietary supplements
Glucomannan
(Allevo®, Konjak tabletter®,
XLS Medical Appetite
Reducer®b etc.)
Gel-forming ﬁber 0e0.8 kg over
3 months
Lo
di
ca
to
Medical devices
Cactus ﬁg ﬁber
(Opuntia ﬁcus-indica)
(Litramine®, XLS Medical
Fat Binder®)
Fat binder plus appetite
suppressant
(dietary ﬁber and plant
extracts from
Opuntia ﬁcus-indica)
2e3% over 3e6
months
W
White bean
(Phaseolus vulgaris)
extract.
(XLS Medical
Carb Blocker®)
Alpha-amylase inhibitor 2% over 6 months G
sy
an
Pharmaceutical
compoundsa
Orlistat
(Alli®, Xenical®)
Lipase-inhibitor 1e2% for low-dose
60 mg (Alli®),
and 3% for high-
dose 120 mg
(Xenical®)
G
sy
oi
co
Liraglutide 3 mg
(Saxenda®)
GLP-agonist e enhances
satiety and reduces
energy intake
5e7% over 3e12
months
G
vo
re
Topiramate/Phentermine
(Qsiva®)
Reduced energy intake by
suppression of appetite
7e8% over 1e2 years. Ph
ca
st
To
CN
si
Naltrexone/bupropion
(Mysimba®)
Reduced energy intake by
suppression of appetite
3e5% over 3e6
months
G
m
SGLT-2 Inhibitors
(Dapagliﬂozin,
Canagliﬂozin,
Empagliﬂozin)
Increased excretion of
glucose in urine
2e4% over 3e6
months,
maintained
for up to 4 years
U
ge
a For the pharmaceutical compounds the weight loss efﬁcacy results are based on lar
generally are small and of short-term duration.
b XLS Medical Appetite Reducer is licensed as a medical deviceglucomannan, and we found it questionable that they provide the
required 3 g per day.
The evidence to substantiate the weight loss claim seems weak.
There are no studies lasting more than 3 months. A meta-analysis
from 2008 found a signiﬁcant weight loss by glucomannan of
0.79 kg greater than placebo (Sood et al., 2008). However, more
recent and updated meta-analyses of the randomized trials did not
ﬁnd that glucomannan added any weight loss to a diet (Zalewski
et al., 2015a, 2015b) (Table 1).
4. Medical devices
4.1. Cactus ﬁg extract (Litramine®, XLS Medical Fat Binder®)
Litramine® is patented ﬁber complex made from dry leaves of
the ﬁg cactus opuntia ﬁcus-indica. The leaves from this cactus are
rich in ﬁber which can bind to fat in the upper part of theof overweight and obesity in Scandinavian countries.
dverse effects Status Comments
ose stools and
arrhea. Tablets may
use GI blockage due
swelling
Approved by
EFSA (EU) for weight
loss claim providing an
intake of 3 g/day
None of the products have
declared their content of
glucomannan, and it is
questionable they provide 1 g/
dose. Newer meta-analyses
question any weight loss
efﬁcacy of 3 g/day.
ell tolerated Approved medical
device
Long term studies lacking
astrointestinal
mptoms (bloating
d constipation)
Approved medical
device
Long term studies lacking
astrointestinal
mptoms (diarrhea,
ly leakage if non-
mpliant)
Approved in EU:
high dose on
prescription,
low dose OTC
Long-term studies support
efﬁcacy and safety over
4 years
I symptoms (nausea,
miting). Dose-
lated
Approved on
prescription in
USA and EU
Injectable, once daily
entermine:
rdiovascular
imulation.
piramate:
Serelated
de effects
Approved on
prescription
in the US, not EU
I symptoms, dry
outh
Approved on
prescription in US
and EU
Concern about long term
side effects
rinary tract and
nital infections
Approved for T2D,
not for non-diabetic
obesity.
ge-scale studies, whereas the studies for dietary supplements and medical devices
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enclosed in a gel covering, which can no longer be absorbed and
hence is eliminated undigested while trapping some fat, helping in
achieving a negative energy balance. Some studies suggest that
Litramine® also has a satiety effect since the gel results in a more
ﬁrm structure of the intestinal content, causing a delay in stomach
emptying and therefore possibly a longer feeling of satiety. Litr-
amine® is not absorbed in the body and in the reported clinical
studies tolerability has been rated as very good with few excep-
tions. In a recent review the efﬁcacy and safety of Litramine® has
been summarized by the research group from which most of the
published work on this compound stems (Chong et al., 2014).
In a study by Uebelhack et al. (2014) the dietary fat binding
capacity of Litramine® ﬁber was determined through analysis of
fecal fat excretion in healthy volunteers. Two 24-hour feces sam-
ples were collected during both the baseline and treatment periods
for analysis of the fat content. Subjects given cactus ﬁber showed a
signiﬁcantly increased fecal fat excretion compared with placebo
(16% vs 5%, P < 0.001). In a three-month study 123 obese over-
weight subjects were treated with Litramine® or placebo (Grube
et al., 2013).
The study comprised a two-week run-in phase and an initial 12-
week trial phase. The initial BMI-value of the group was 29.6 kg/m2
and the middle age 45 years. The mean body weight change from
baseline was 3.8 ± 1.8 kg in the Litramine® group vs. 1.4 ± 2.6 kg in
the controls (p < 0.001), and 76% of subjects on Litramine® versus
28% on placebo lost at least 3% of the body weight (p < 0.001).
Another double-blind, randomized, placebo-controlled study in
overweight and obese subjects lasting 24 weeks demonstrated that
after 24weeks the number of responders was higher in Litramine®-
treated subjects than in placebo individuals. At the end of the study
the difference in weight between the groups was 2.2 kg; 92% in the
Litramine® group vs. 25% in controls managed to maintain the
weight loss (Grube et al., 2015).
The Litramine® dose is 2 tablets three times daily, which means
drug intake with every meal, since the compound is intended to
interferewith fat absorption and satiety feelings in connectionwith
ordinary food intake.
4.2. White bean extract e Phaseolus vulgaris (XLS Medical Carb
Blocker®)
A number of drugs (e.g. acarbose) and naturally occurring food
components contain alpha-amylase inhibitors and are used to
reduce post-prandial blood glucose excursions, enhance satiety by
reducing the glycemic index of meals, and to reduce the absorption
of carbohydrate to increase the loss of calories from the GI tract.
Common beans contain various forms of alpha-amylase inhibitors,
and extracts have been developed to increase the efﬁcacy of the
enzyme inhibition to achieve clinical efﬁcacy. In particular, an
extract from thewhite bean (Phaseolus vulgaris) has been tested in a
number of trials (for review see Barrett and Udani, 2011). A four
week, placebo-controlled, RCT trial in 25 subjects found a non-
signiﬁcant weight loss difference of 0.6 kg in favor of the white
bean extract, but among the subjects with a high carbohydrate
intake the difference was more pronounced (3 kg) (Udani and
Singh, 2007). A subsequent 12 week, double-blind, placebo-
controlled RCT randomized 124 subjects with a BMI 25e35 kg/m2
to a supplement with white bean extract in combination with a
mild diet (Grube et al., 2014). After the 12 week weight loss inter-
vention weight loss was 2.91 versus 0.92 kg, in the verum and
placebo groups respectively (P < 0.001). The weight loss in favor of
the white bean extract, 2.0 kg, was due mainly to a reduction in
body fat mass of 1.6 kg, which was also reﬂected in a 1.4 cm
reduction in waist circumference. In a subsequent 24 weeks, openlabel, weight maintenance follow-up phase the majority of subjects
maintained the weight loss. The adverse events were few and
probably unrelated to the treatment.5. Conclusion
In addition todiet, exercise, andbehaviormodiﬁcation, a number
of treatment options are available for overweight and obese patients
who do not qualify for bariatric surgery. For overweight subjects
dietary supplements (approved as medical devices) provide an op-
tion that adds 2e3% (or kg) to the diet-induced weight loss, and
slightly more with orlistat, the use of which, however requires a
strict low-fat diet to avoid tolerability problems due to GI tract side
effects. These compoundsact locally in thegastrointestinal tract, and
have not been found to possess systemic adverse effects. The newer
pharmaceutical agents provide more weight loss, and large-scale
studies are available to document long-term effects, effects on pre-
vention of T2D, and better safety information in general. We
conclude that studies of the non-pharmacological agents are
generally small in size, and adverse effects are not well established.
In regard to pharmacological agents, there is a lack of studies that
combine the available treatmentoptions to assess additive effects on
weight loss and maintenance.Conﬂicts of Interest
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